TrialSignal
Clinical trial intelligence report
Exploratory Clinical Study of PD-1 Knockout Targeting MUC1 CAR-T Cells (AJMUC1) in the Treatment of MUC1-positive Advanced Breast Cancer
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT05812326-Jul 28, 2026
NCT ID
NCT05812326
Status
COMPLETED
Phase
Phase 1/2
Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Executive brief
Investment-Ready Snapshot
The AJMUC1 clinical trial, sponsored by Sun Yat-Sen Memorial Hospital, explores a novel immunotherapy approach for advanced MUC1-positive breast cancer, a population with limited effective treatment options. The trial's completion in November 2022 positions it for potential market entry, contingent on favorable safety and efficacy results. The competitive landscape includes established CAR-T therapies and emerging immunotherapies targeting similar malignancies. The success of AJMUC1 could provide a unique therapeutic avenue, particularly for patients who have exhausted standard treatment options, thereby addressing a significant unmet medical need. Diligence should focus on the trial's safety profile, potential market size, and the regulatory pathway for CAR-T therapies in China and globally.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT05812326
Indication
Advanced Breast Cancer
Modality
gene therapy
Target
PD-1 knockout anti-MUC1 CAR-T cells targeting aberrantly glycosylated MUC1 protein.
Intervention
AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.